Literature DB >> 23630218

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

M Catherine Pietanza1, Ethan M Basch, Alex Lash, Lawrence H Schwartz, Michelle S Ginsberg, Binsheng Zhao, Marwan Shouery, Mary Shaw, Lauren J Rogak, Manda Wilson, Aaron Gabow, Marcia Latif, Kai-Hsiung Lin, Qinfei Wu, Samantha L Kass, Claire P Miller, Leslie Tyson, Dyana K Sumner, Alison Berkowitz-Hergianto, Camelia S Sima, Mark G Kris.   

Abstract

PURPOSE: In clinical trials, traditional monitoring methods, paper documentation, and outdated collection systems lead to inaccuracies of study information and inefficiencies in the process. Integrated electronic systems offer an opportunity to collect data in real time. PATIENTS AND METHODS: We created a computer software system to collect 13 patient-reported symptomatic adverse events and patient-reported Karnofsky performance status, semi-automated RECIST measurements, and laboratory data, and we made this information available to investigators in real time at the point of care during a phase II lung cancer trial. We assessed data completeness within 48 hours of each visit. Clinician satisfaction was measured.
RESULTS: Forty-four patients were enrolled, for 721 total visits. At each visit, patient-reported outcomes (PROs) reflecting toxicity and disease-related symptoms were completed using a dedicated wireless laptop. All PROs were distributed in batch throughout the system within 24 hours of the visit, and abnormal laboratory data were available for review within a median of 6 hours from the time of sample collection. Manual attribution of laboratory toxicities took a median of 1 day from the time they were accessible online. Semi-automated RECIST measurements were available to clinicians online within a median of 2 days from the time of imaging. All clinicians and 88% of data managers felt there was greater accuracy using this system.
CONCLUSION: Existing data management systems can be harnessed to enable real-time collection and review of clinical information during trials. This approach facilitates reporting of information closer to the time of events, and improves efficiency, and the ability to make earlier clinical decisions.

Entities:  

Mesh:

Year:  2013        PMID: 23630218      PMCID: PMC4878068          DOI: 10.1200/JCO.2012.45.8117

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  42 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Statistical design in phase II clinical trials and its application in breast cancer.

Authors:  Francesco Perrone; Massimo Di Maio; Ermelinda De Maio; Paolo Maione; Alessandro Ottaiano; Matilde Pensabene; Giuseppe Di Lorenzo; Alessandra Vernaglia Lombardi; Giuseppe Signoriello; Ciro Gallo
Journal:  Lancet Oncol       Date:  2003-05       Impact factor: 41.316

3.  Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.

Authors:  Laura C Michaelis; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

4.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

5.  Web-based multi-center data management system for clinical neuroscience research.

Authors:  Alexander Pozamantir; Hedok Lee; Joab Chapman; Isak Prohovnik
Journal:  J Med Syst       Date:  2010-02       Impact factor: 4.460

6.  A partnership approach for Electronic Data Capture in small-scale clinical trials.

Authors:  Joshua D Franklin; Alicia Guidry; James F Brinkley
Journal:  J Biomed Inform       Date:  2011-05-30       Impact factor: 6.317

Review 7.  Electronic toxicity monitoring and patient-reported outcomes.

Authors:  Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner
Journal:  Cancer J       Date:  2011 Jul-Aug       Impact factor: 3.360

8.  Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Authors:  M Catherine Pietanza; Kyuichi Kadota; Kety Huberman; Camelia S Sima; John J Fiore; Dyana K Sumner; William D Travis; Adriana Heguy; Michelle S Ginsberg; Andrei I Holodny; Timothy A Chan; Naiyer A Rizvi; Christopher G Azzoli; Gregory J Riely; Mark G Kris; Lee M Krug
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

9.  Three-dimensional lung tumor segmentation from x-ray computed tomography using sparse field active models.

Authors:  Joseph Awad; Amir Owrangi; Lauren Villemaire; Elaine O'Riordan; Grace Parraga; Aaron Fenster
Journal:  Med Phys       Date:  2012-02       Impact factor: 4.071

10.  Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Authors:  Robert G Maki; David R D'Adamo; Mary L Keohan; Michael Saulle; Scott M Schuetze; Samir D Undevia; Michael B Livingston; Matthew M Cooney; Martee L Hensley; Monica M Mita; Chris H Takimoto; Andrew S Kraft; Anthony D Elias; Bruce Brockstein; Nathalie E Blachère; Mark A Edgar; Lawrence H Schwartz; Li-Xuan Qin; Cristina R Antonescu; Gary K Schwartz
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

View more
  14 in total

1.  Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up.

Authors:  Fabrice Denis; Louise Viger; Alexandre Charron; Eric Voog; Christophe Letellier
Journal:  Support Care Cancer       Date:  2013-09-01       Impact factor: 3.603

2.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

3.  Detection of lung cancer relapse using self-reported symptoms transmitted via an internet web-application: pilot study of the sentinel follow-up.

Authors:  Fabrice Denis; Louise Viger; Alexandre Charron; Eric Voog; Olivier Dupuis; Yoann Pointreau; Christophe Letellier
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

4.  Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.

Authors:  M C Pietanza; Matthew D Hellmann; John J Fiore; Stephanie Smith-Marrone; Ethan M Basch; Lawrence H Schwartz; Michelle S Ginsberg; Marwan Shouery; Samantha K Newman; Mary Shaw; Lauren J Rogak; Alex E Lash; Patrick Hilden; Mark G Kris
Journal:  J Thorac Oncol       Date:  2016-03-08       Impact factor: 15.609

Review 5.  Caring for caregivers and patients: Research and clinical priorities for informal cancer caregiving.

Authors:  Erin E Kent; Julia H Rowland; Laurel Northouse; Kristin Litzelman; Wen-Ying Sylvia Chou; Nonniekaye Shelburne; Catherine Timura; Ann O'Mara; Karen Huss
Journal:  Cancer       Date:  2016-03-17       Impact factor: 6.860

6.  Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.

Authors:  Ethan Basch; William A Wood; Deborah Schrag; Camelia S Sima; Mary Shaw; Lauren J Rogak; Mark G Kris; Marwan Shouery; Antonia Bennett; Thomas Atkinson; M Catherine Pietanza
Journal:  Clin Trials       Date:  2015-11-04       Impact factor: 2.486

7.  Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.

Authors:  S A Hayes; M C Pietanza; D O'Driscoll; J Zheng; C S Moskowitz; M G Kris; M S Ginsberg
Journal:  Eur J Radiol       Date:  2016-01-02       Impact factor: 3.528

8.  Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.

Authors:  Gita Thanarajasingam; Pamela J Atherton; Paul J Novotny; Charles L Loprinzi; Jeff A Sloan; Axel Grothey
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

9.  Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: A prospective feasibility study.

Authors:  Aaron D Falchook; Gregg Tracton; Lori Stravers; Mary E Fleming; Anna C Snavely; Jeanne F Noe; David N Hayes; Juneko E Grilley-Olson; Jared M Weiss; Bryce B Reeve; Ethan M Basch; Bhishamjit S Chera
Journal:  Adv Radiat Oncol       Date:  2016-02-18

10.  Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Authors:  C H Li; R R Bies; Y Wang; M R Sharma; S Karovic; L Werk; M J Edelman; A A Miller; E E Vokes; A Oto; M J Ratain; L H Schwartz; M L Maitland
Journal:  Clin Transl Sci       Date:  2016-01-21       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.